个体化免疫耐受的诱导与调节性T细胞

吕凌; 倪绪浩

doi:10.3969/j.issn.1674-7445.2020.01.002

个体化免疫耐受的诱导与调节性T细胞

doi: 10.3969/j.issn.1674-7445.2020.01.002

吕凌^,,
倪绪浩

210009 南京医科大学第一附属医院肝胆中心

基金项目:

国家自然科学基金优秀青年基金 81522020

国家自然科学基金重大研究计划 91442117

科技部863青年科学家专题 2015AA020932

国家自然科学基金面上项目 81571564

江苏省重点研发计划 BE2016766

江苏省科技厅临床前沿技术项目 BE2016766

详细信息

作者简介:
吕凌，医学博士，副主任医师，教授，博士研究生导师，国家百千万人才计划获得者，国家优秀青年基金获得者，科技部863青年科学家。现任江苏省细胞工程研究院执行院长、江苏省转化医学研究院副院长、南京医科大学转化医学研究院副院长、南京医科大学第一附属医院大外科副主任，作为主要发起人之一创建了江苏省研究型医院学会并任副会长。担任中国工程院院刊《Engineering》细胞治疗专刊的执行主编、《Annual of Translational Medicine》、《Translational Cancer Research》副主编，《器官移植》杂志编委，在《Nature Reviews Immunology》、《Cancer Discovery》、《EMBO Journal》、《Hepatology》、《Blood》、《PNAS》等杂志发表SCI论文70余篇。兼任中华医学会微免分会移植免疫学组副组长，中国免疫学会青年工作委员会副主任委员，中国医药质量管理协会细胞治疗质量控制与研究专业委员会常务委员，江苏省免疫学会第四届理事会常务理事，江苏省免疫学会区域与移植免疫专业委员会主任委员，江苏省免疫学会区域与移植免疫专业委员会肝脏病学组常务委员，江苏省免疫学会第一届青年工作委员会副主任委员，江苏省抗癌协会肝癌专业委员会委员兼秘书。获江苏省五四青年奖章，中国免疫学会青年学者奖，江苏省333高层次人才（二层次）、江苏省六大高峰人才、江苏省医学领军人才，江苏省首届青年双创英才称号，江苏省优秀科技工作者等称号。获得江苏省科学技术进步奖一等奖、高等学校科学研究优秀成果奖-科技进步奖、中华医学科技奖、华夏医学科技奖等省部级以上科技奖励8项。连续4年入选爱思唯尔中国“高被引学者”医学类榜单（代表在该领域的国际影响力）。国家发明专利授权3项。主编或参编医学专著7部

通讯作者:
吕凌，Email：lvling@njmu.edu.cn

中图分类号: R617, R392.4
计量
- 文章访问数: 304
- HTML全文浏览量: 80
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-12
- 网络出版日期: 2021-01-19
- 刊出日期: 2020-01-15

Individualized induction of immune tolerance and regulatory T cell

Lyu Ling^,,
Ni Xuhao

Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China

More Information

Corresponding author: Lyu Ling, Email:lvling@njmu.edu.cn

摘要

摘要: 免疫耐受的诱导是器官移植免疫领域的重要组成部分和最高追求目标，它基于对移植抗原识别、提呈以及免疫系统的激活和应答等免疫学本质的认识。但是，在成功诱导免疫耐受之前，如何对器官移植受者实施个体化免疫耐受诱导，从而使免疫抑制剂和个体化治疗措施实现最优化的搭配，来达到预防和治疗排斥反应的效果最佳、不良反应最小的理想状态，仍然是移植工作者不断探索和仍未解决的难题。本文综合国际核心期刊报道内容，从免疫耐受诱导机制、可操作性免疫耐受的实现、个体化免疫耐受诱导新策略及调节性T细胞在个体化免疫耐受中的应用，并结合本中心调节性T细胞临床和基础研究成果综合讨论个体化免疫耐受诱导策略和未来展望。
- 器官移植 /
- 免疫耐受 /
- 可操作性免疫耐受 /
- 免疫排斥反应 /
- 移植免疫 /
- 调节性T细胞 /
- 转化医学
Abstract: The induction of immune tolerance is an essential component and the utmost goal in the field of organ transplantation immunity, which depends upon the recognition and presentation of transplantation antigens, the activation and response of the immune system and other immune essence. However, before successfully inducing immune tolerance, how to carry out individualized induction of immune tolerance in organ transplant recipients to optimize the combination of immunosuppressive agents and individualized treatment and achieve the ideal state of optimal prevention and treatment of immune rejection and minimal adverse reactions, remains to be further resolved by the organ transplantation practitioners. Based on the reports of international core journals, the individualized induction strategy of immune tolerance and the future prospects were reviewed in this article from the following aspects including the mechanism underlying induction of immune tolerance, realization of operational immune tolerance, novel strategy of individualized induction of immune tolerance and application of regulatory T cell in individualized immune tolerance in combination with clinical and laboratory research results of regulatory T cell in our center.
- Organ transplantation /
- Immune tolerance /
- Operational immune tolerance /
- Immune rejection /
- Transplantation immunity /
- Regulatory T cell /
- Translational medicine

HTML全文

参考文献(23)

[1]	MOREAU A, VAREY E, ANEGON I, et al. Effector mechanisms of rejection[J]. Cold Spring Harb Perspect Med, 2013, 3(11). DOI: 10.1101/cshperspect.a015461.
[2]	KRZYMOWSKI T, STEFAŃCZYK-KRZYMOWSKA S. Advances in understanding the physiological mechanism of maternal immune tolerance to the embryo[J]. Reprod Biol, 2012, 12(3):265-270. DOI: 10.1016/j.repbio.2012.10.004.
[3]	SCHIETINGER A, GREENBERG PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction[J]. Trends Immunol, 2014, 35(2):51-60. DOI: 10.1016/j.it.2013.10.001.
[4]	HU B, YANG XB, SANG XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review[J]. Med Oncol, 2019, 36(11):94. DOI: 10.1007/s12032-019-1316-7.
[5]	陈瑜, 于姝, 滕飞, 等.自身免疫调节因子与中枢免疫耐受[J].现代免疫学, 2010, 30(1):1-4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shmyxzz201001001 CHEN Y, YU S, TENG F, et al. Autoimmune regulatory factors and central immune tolerance [J]. Curr Immunol, 2010, 30(1):1-4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shmyxzz201001001
[6]	郑配国, 马攀红, 符含笑, 等.可溶性髓鞘少突胶质细胞糖蛋白(MOG)诱导实验性自身免疫性脑脊髓炎(EAE)小鼠免疫耐受的机制[J].细胞与分子免疫学杂志, 2018, 34(5):414-420. http://d.old.wanfangdata.com.cn/Periodical/xbyfzmyxzz201805006 ZHENG PG, MA PH, FU HX, et al. Mechanism of immune tolerance induced by soluble myelin oligodendrocyte glycoprotein in mice with experimental autoimmune encephalomyelitis[J]. Chin J Cell Mol Immunol, 2018, 34(5):414-420. http://d.old.wanfangdata.com.cn/Periodical/xbyfzmyxzz201805006
[7]	PARAF A, GUéRIN-MARCHAND C, AUBRY J, et al. Mechanism of immune stimulation and tolerance based on an hypothesis on the cell division mechanism directed by the cell membrane[J]. Ann Immunol (Paris), 1975, 126C(4):423-430. http://cn.bing.com/academic/profile?id=efe83146bc89aaf8dd39a35747e11b22&encoded=0&v=paper_preview&mkt=zh-cn
[8]	MAKKOUK A, WEINER GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge[J]. Cancer Res, 2015, 75(1):5-10. DOI: 10.1158/0008-5472.CAN-14-2538.
[9]	KOSIEWICZ MM, ALARD P, LIANG S, et al. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand[J]. Int Immunol, 2004, 16(5):697-706. doi: 10.1093/intimm/dxh067
[10]	THAPA P, FARBER DL. The role of the thymus in the immune response[J]. Thorac Surg Clin, 2019, 29(2):123-131. DOI: 10.1016/j.thorsurg.2018.12.001.
[11]	GEENEN V. History of the thymus: from an "accident of evolution" to the programming of immunological self-tolerance[J]. Med Sci (Paris), 2017, 33(6/7):653-663. DOI: 10.1051/medsci/20173306024.
[12]	朱小慧, 盛德乔.免疫耐受机制的研究进展[J].细胞与分子免疫学杂志, 2011, 27(5):121-123. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xbyfzmyxzz201105041 ZHU XH, SHENG DQ. Research progress of immune tolerance mechanism[J]. Chin J Cell Mol Immunol, 2011, 27(5):121-123. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xbyfzmyxzz201105041
[13]	伍仙凤, 盛德乔.外周免疫耐受机制的研究进展[J].免疫学杂志, 2013, 29(8):710-714, 719. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=myxzz201308015 WU XF, SHENG DQ. Progress in mechanisms of peripheral immunological tolerance[J]. Immunol J, 2013, 29(8):710-714, 719. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=myxzz201308015
[14]	BLACK CK, TERMANINI KM, AGUIRRE O, et al. Solid organ transplantation in the 21st century[J]. Ann Transl Med, 2018, 6(20):409. DOI: 10.21037/atm.2018.09.68.
[15]	GRUNEBAUM E, AVITZUR Y. Liver-associated immune abnormalities[J]. Autoimmun Rev, 2019, 18(1):15-20. DOI: 10.1016/j.autrev.2018.06.016.
[16]	NALESNIK MA, RAO AS, FURUKAWA H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients[J]. Transplantation, 1997, 63(9):1200-1205. doi: 10.1097/00007890-199705150-00002
[17]	GIRLANDA R, VILCA-MELENDEZ H, SRINIVASAN P, et al. Immunosuppression withdrawal after auxiliary liver transplantation for acute liver failure[J]. Transplant Proc, 2005, 37(4):1720-1721. doi: 10.1016/j.transproceed.2005.03.141
[18]	ICHIKAWA T, TAURA N, MIYAAKI H, et al. β-cell function prior to liver transplantation contributes to post-operative diabetes[J]. Biomed Rep, 2016, 5(6):749-757. DOI: 10.3892/br.2016.788.
[19]	TZAKIS AG, KATO T, NISHIDA S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation[J]. Transplantation, 2003, 75(9):1512-1517. doi: 10.1097/01.TP.0000060250.50591.39
[20]	ZENG H, ZHANG R, JIN B, et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance[J]. Cell Mol Immunol, 2015, 12(5):566-571. DOI: 10.1038/cmi.2015.44.
[21]	TODO S, YAMASHITA K, GOTO R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology, 2016, 64(2):632-643. DOI: 10.1002/hep.28459.
[22]	ZWANG NA, LEVENTHAL JR. Cell therapy in kidney transplantation: focus on regulatory T cells[J]. J Am Soc Nephrol, 2017, 28(7):1960-1972. DOI: 10.1681/ASN.2016111206.
[23]	SAFINIA N, GRAGEDA N, SCOTTà C, et al. Cell therapy in organ transplantation: our experience on the clinical translation of regulatory T cells[J]. Front Immunol, 2018, 9:354. DOI: 10.3389/fimmu.2018.00354.